Timothy J. Wilt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Timothy J. Wilt has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Roderick MacDonald
VAMC; General Internal Medicine (111-0); One Veterans Drive Minneapolis Minnesota USA 55417
18 shared publicationsIndy Rutks
VAMC; Department of Internal Medicine (111-0); One Veterans Drive Minneapolis Minnesota USA 55417
6 shared publicationsRobert L. Kane
From University of Minnesota and Minneapolis Veterans Affairs Medical Center; Center for Chronic Disease Outcomes Research, Minneapolis Veterans Affairs Medical Center; Minnesota Evidence-based Practice Center; and University of Minnesota School of Public Health, Minneapolis, Minnesota
5 shared publications- Brent C. Taylor
VA Health Service Research & Development (HSR&D) Center for Care Delivery and Outcomes Research (CCDOR), Minneapolis VA Health Care System (VAHCS) Minneapolis Minnesota USA
4 shared publications Areef Ishani
VA Medical Center; Department of Medicine (111); One Veterans Drive Minneapolis Minnesota USA 55417
3 shared publications- Tatyana Arstakovna Shamliyan
American College of Physicians, Philadelphia, Pennsylvania
3 shared publications
Latest Publications
- Open Access
- 14 September 2012
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2012 (45) , 184-190
The Prostate Cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and Baseline Results of a Randomized Controlled Trial Comparing Radical Prostatectomy With Watchful Waiting for Men With Clinically Localized Prostate Cancer
Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. In the United States, 90% of men with prostate cancer are more than age 60 years, diagnosed by early detection with the prostate-specific antigen (PSA) blood test, and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting (WW), surgery to remove the prostate gland (radical prostatectomy), external-beam radiation therapy and interstitial radiation therapy (brachytherapy), and androgen deprivation. Little is known about the relative effectiveness and harms of treatments because of the paucity of randomized controlled trials. The Department of Veterans Affairs/National Cancer Institute/Agency for Healthcare Research and Quality Cooperative Studies Program Study #407:Prostate Cancer Intervention Versus Observation Trial (PIVOT), initiated in 1994, is a multicenter randomized controlled trial comparing radical prostatectomy with WW in men with clinically localized prostate cancer. We describe the study rationale, design, recruitment methods, and baseline characteristics of PIVOT enrollees. We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy vs WW conducted in Scandinavia. We screened 13 022 men with prostate cancer at 52 US medical centers for potential enrollment. From these, 5023 met initial age, comorbidity, and disease eligibility criteria, and a total of 731 men agreed to participate and were randomized. The mean age of enrollees was 67 years. Nearly one-third were African American. Approximately 85% reported that they were fully active. The median PSA was 7.8ng/mL (mean 10.2ng/mL). In three-fourths of men, the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise. Using previously developed tumor risk categorizations incorporating PSA levels, Gleason histologic grade, and tumor stage, it was found that approximately 40% had low-risk, 34% had medium-risk, and 21% had high-risk prostate cancer based on local histopathology. Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the United States and quite different from men in the Scandinavian trial. PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States. Results will yield important information regarding the relative effectiveness and harms of surgery compared with WW for men with predominately PSA-detected clinically localized prostate cancer.
- 14 September 2012
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2012 (45) , 184-190
Open AccessThe Prostate Cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and Baseline Results of a Randomized Controlled Trial Comparing Radical Prostatectomy With Watchful Waiting for Men With Clinically Localized Prostate Cancer
Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. In the United States, 90% of men with prostate cancer are more than age 60 years, diagnosed by early detection with the prostate-specific antigen (PSA) blood test, and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting (WW), surgery to remove the prostate gland (radical prostatectomy), external-beam radiation therapy and interstitial radiation therapy (brachytherapy), and androgen deprivation. Little is known about the relative effectiveness and harms of treatments because of the paucity of randomized controlled trials. The Department of Veterans Affairs/National Cancer Institute/Agency for Healthcare Research and Quality Cooperative Studies Program Study #407:Prostate Cancer Intervention Versus Observation Trial (PIVOT), initiated in 1994, is a multicenter randomized controlled trial comparing radical prostatectomy with WW in men with clinically localized prostate cancer. We describe the study rationale, design, recruitment methods, and baseline characteristics of PIVOT enrollees. We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy vs WW conducted in Scandinavia. We screened 13 022 men with prostate cancer at 52 US medical centers for potential enrollment. From these, 5023 met initial age, comorbidity, and disease eligibility criteria, and a total of 731 men agreed to participate and were randomized. The mean age of enrollees was 67 years. Nearly one-third were African American. Approximately 85% reported that they were fully active. The median PSA was 7.8ng/mL (mean 10.2ng/mL). In three-fourths of men, the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise. Using previously developed tumor risk categorizations incorporating PSA levels, Gleason histologic grade, and tumor stage, it was found that approximately 40% had low-risk, 34% had medium-risk, and 21% had high-risk prostate cancer based on local histopathology. Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the United States and quite different from men in the Scandinavian trial. PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States. Results will yield important information regarding the relative effectiveness and harms of surgery compared with WW for men with predominately PSA-detected clinically localized prostate cancer.
- 12 December 2011
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 171 (22) , 2046-2048
Screening: Simple Messages . . . Sometimes
Opinion from JAMA Internal Medicine — Screening — Simple Messages . . . Sometimes — Comment on ”Likelihood That a Woman With Screen-Detected Breast Cancer Has Had Her “Life Saved” by That Screening“
- 12 December 2011
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 171 (22) , 2046-2048
Screening: Simple Messages . . . Sometimes
Opinion from JAMA Internal Medicine — Screening — Simple Messages . . . Sometimes — Comment on ”Likelihood That a Woman With Screen-Detected Breast Cancer Has Had Her “Life Saved” by That Screening“
- 7 September 2011
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2011 (9) , CD003851
Terazosin for benign prostatic hyperplasia
This review has been withdrawn until such time its authors can update it. Térazosine dans l'hyperplasie prostatique bénigne La présente revue a été retirée jusqu'à ce que ses auteurs procèdent à sa mise à jour.
- 7 September 2011
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2011 (9) , CD003851
Terazosin for benign prostatic hyperplasia
This review has been withdrawn until such time its authors can update it. Térazosine dans l'hyperplasie prostatique bénigne La présente revue a été retirée jusqu'à ce que ses auteurs procèdent à sa mise à jour.
- 7 September 2011
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2011 (9) , CD002081
Tamsulosin for benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate which can result in bothersome lower urinary tract symptoms. The treatment goal for men with BPH is to relieve these bothersome symptoms. This systematic review assessed the effects of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) compatible with BPH. Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, Cochrane Library), by checking bibliographies, and by contacting manufacturers and researchers. Trials were eligible if they (1) randomized men with BPH to receive tamsulosin in comparison with placebo, other BPH medications or surgical interventions and (2) included clinical outcomes such as urologic symptom scales, symptoms, or urodynamic measurements, and (3) had a treatment duration of 30 days or longer. Eligibility was assessed by at least two independent observers. Information on patients, interventions, and outcomes were extracted by at least two independent reviewers using a standard form. The main outcome measure for comparing the effectiveness of tamsulosin with placebo, medical or surgical interventions was the change in urologic symptom scale scores. Secondary outcomes included changes in urinary flow measures (peak urine flow rate). The main outcome measure for adverse effects was the number of men reporting adverse effects. Fourteen studies involving 4122 subjects met inclusion criteria. Study duration ranged from 4 to 26 weeks, and no placebo-controlled study lasted longer than 13 weeks. The mean age of subjects was 64 years. Baseline symptom scores and urine flow rates demonstrated that men had moderate LUTS. Tamsulosin improved symptoms and peak urine flow relative to placebo. The weighted mean differences (WMD) for mean change from baseline for the Boyarsky symptom score for 0.4 mg and 0.8 mg doses of tamsulosin relative to placebo were -1.1 points (95% CI = -1.49 to -0.72; 12% improvement) and -1.6 points (95% CI = -2.3 to -1.0; 16% improvement), respectively. The WMD for mean change from baseline in peak urine flow were 1.1 mL/sec (95% CI = 0.59 to 1.51) and 1.1 mL/sec (95% CI= 0.65 to 1.48) for 0.4 mg and 0.8 mg, respectively. Tamsulosin (0.2 mg to 0.4 mg) was as effective as other alpha antagonists and the phytotherapeutic agent Permixon® in improving symptoms and flow rates though the doses of all alpha-antagonists studied may not have been optimal. Discontinuations from treatment for any reason and discontinuations "due to adverse events" were similar in the low dose tamsulosin (0.2 mg) and placebo groups but increased to 16% in trials utilizing a 0.8 mg dose of tamsulosin. Low dose tamsulosin was generally well tolerated although not all the trials reported specific adverse events. The most frequently reported adverse events that were significantly greater than placebo included dizziness, rhinitis and abnormal ejaculation. Adverse effects increased markedly as tamsulosin dosing increased, and were reported in 75% of men receiving the 0.8 mg dose. Men receiving a 0.2 mg dose tamsulosin were less likely to discontinue treatment compared to men receiving terazosin. Tamsulosin provided a small to moderate improvement in urinary symptoms and flow compared to men receiving placebo in men with BPH. Effectiveness was similar to other alpha antagonists and increased only slightly with higher doses. Long term effectiveness and ability to reduce complications due to BPH progression could not be determined. Adverse effects were generally mild but their frequency, including withdrawals, increased substantially with the higher doses that are generally available for treatment.
- 7 September 2011
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2011 (9) , CD002081
Tamsulosin for benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate which can result in bothersome lower urinary tract symptoms. The treatment goal for men with BPH is to relieve these bothersome symptoms. This systematic review assessed the effects of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) compatible with BPH. Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, Cochrane Library), by checking bibliographies, and by contacting manufacturers and researchers. Trials were eligible if they (1) randomized men with BPH to receive tamsulosin in comparison with placebo, other BPH medications or surgical interventions and (2) included clinical outcomes such as urologic symptom scales, symptoms, or urodynamic measurements, and (3) had a treatment duration of 30 days or longer. Eligibility was assessed by at least two independent observers. Information on patients, interventions, and outcomes were extracted by at least two independent reviewers using a standard form. The main outcome measure for comparing the effectiveness of tamsulosin with placebo, medical or surgical interventions was the change in urologic symptom scale scores. Secondary outcomes included changes in urinary flow measures (peak urine flow rate). The main outcome measure for adverse effects was the number of men reporting adverse effects. Fourteen studies involving 4122 subjects met inclusion criteria. Study duration ranged from 4 to 26 weeks, and no placebo-controlled study lasted longer than 13 weeks. The mean age of subjects was 64 years. Baseline symptom scores and urine flow rates demonstrated that men had moderate LUTS. Tamsulosin improved symptoms and peak urine flow relative to placebo. The weighted mean differences (WMD) for mean change from baseline for the Boyarsky symptom score for 0.4 mg and 0.8 mg doses of tamsulosin relative to placebo were -1.1 points (95% CI = -1.49 to -0.72; 12% improvement) and -1.6 points (95% CI = -2.3 to -1.0; 16% improvement), respectively. The WMD for mean change from baseline in peak urine flow were 1.1 mL/sec (95% CI = 0.59 to 1.51) and 1.1 mL/sec (95% CI= 0.65 to 1.48) for 0.4 mg and 0.8 mg, respectively. Tamsulosin (0.2 mg to 0.4 mg) was as effective as other alpha antagonists and the phytotherapeutic agent Permixon® in improving symptoms and flow rates though the doses of all alpha-antagonists studied may not have been optimal. Discontinuations from treatment for any reason and discontinuations "due to adverse events" were similar in the low dose tamsulosin (0.2 mg) and placebo groups but increased to 16% in trials utilizing a 0.8 mg dose of tamsulosin. Low dose tamsulosin was generally well tolerated although not all the trials reported specific adverse events. The most frequently reported adverse events that were significantly greater than placebo included dizziness, rhinitis and abnormal ejaculation. Adverse effects increased markedly as tamsulosin dosing increased, and were reported in 75% of men receiving the 0.8 mg dose. Men receiving a 0.2 mg dose tamsulosin were less likely to discontinue treatment compared to men receiving terazosin. Tamsulosin provided a small to moderate improvement in urinary symptoms and flow compared to men receiving placebo in men with BPH. Effectiveness was similar to other alpha antagonists and increased only slightly with higher doses. Long term effectiveness and ability to reduce complications due to BPH progression could not be determined. Adverse effects were generally mild but their frequency, including withdrawals, increased substantially with the higher doses that are generally available for treatment.
- 11 May 2011
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2011 (5) , CD001042
Cernilton for benign prostatic hyperplasia
Authors have indicated they are not going to update this review. Cernilton dans l'hyperplasie prostatique bénigne Contexte L'hyperplasie prostatique bénigne (HPB), une hypertrophie non maligne de la prostate, peut provoquer des symptômes obstructifs et irritants des voies urinaires inférieures (SVUI). L'utilisation pharmacologique des plantes et des herbes (phytothérapie) pour le traitement des SVUI associés à une HPB est en constante progression. Le Cernilton, préparé à partir de pollen de fleur de seigle, Secale cereale, est l'un des nombreux agents phytothérapeutiques disponibles pour le traitement de l'HPB. Objectifs L'objectif de cette revue systématique est d'évaluer les effets du Cernilton sur les symptômes urinaires et les mesures de débit chez les hommes souffrant d'une hyperplasie prostatique bénigne (HPB). Stratégie de recherche documentaire Des essais ont été recherchés dans des bases de données générales et spécialisées informatisées (MEDLINE, EMBASE, Cochrane Library, Phytodok), en consultant les bibliographies et en contactant les fabricants et les chercheurs. Critères de sélection Les essais étaient éligibles à condition d'être : (1) des essais contrôlés randomisés ou des essais cliniques contrôlés comparant le Cernilton à un placebo ou à d'autres médicaments contre l'HPB chez les hommes souffrant d'HPB et (2) des résultats cliniques inclus comme des échelles de symptômes urologiques, des symptômes ou des mesures urodynamiques. Recueil et analyse des données Au moins deux évaluateurs indépendants ont extrait des informations concernant les patients, les interventions et les résultats à l'aide d'un formulaire standard. Le critère de jugement principal permettant de comparer les effets du Cernilton à ceux d'un placebo et de traitements standard contre l'HPB était une modification au niveau des échelles de symptômes urologiques. Les critères de jugement secondaires incluaient des modifications au niveau de la nycturie et des mesures urodynamiques (débit urinaire moyen et de pointe, volume résiduel, taille de la prostate). Le critère de jugement principal concernant les effets secondaires était le nombre d'hommes signalant des effets secondaires. Résultats principaux Des hommes, au nombre de 444, ont été recrutés dans deux essais contrôlés par placebo et deux essais comparatifs d'une durée variant de 12 à 24 semaines. Trois études utilisaient une méthode en double aveugle, bien que l'assignation secrète du traitement soit peu claire dans l'ensemble des études. Le Cernilton améliorait les « symptômes urinaires signalés » (pourcentage signalant des symptômes satisfaisants ou leur amélioration) par rapport à un placebo et au Tadenan. Le risque relatif (RR) pondéré d'une amélioration signalée était de 2,40 (IC à 95 % = 1,21 à 4,75) par rapport à un placebo et le RR pondéré était de 1,42 (IC à 95 % = 1,21 à 4,75) par rapport au Tadenan. Le Cernilton réduisait la nycturie par rapport à un placebo et au Paraprost. Comparé à un placebo, le RR pondéré était de 2,05 (IC à 95 % = 1,41 à 3,00) et comparée au Paraprost, la DMP était de - 0,40 fois par soir (IC à 95 % = - 0,73 à - 0,07). Le Cernilton n'était pas plus efficace qu'un placebo ou les agents de l'étude comparative à améliorer les taux de débit urinaire, le volume résiduel ou la taille de la prostate. Les événements indésirables étaient rares et légers. Le taux d'arrêts prématurés du Cernilton était de 4,8 % par rapport à 2,7 % pour le placebo et 5,2 % pour le Paraprost. Conclusions des auteurs Les essais concernant le Cernilton analysés étaient limités par une durée courte, un nombre limité de personnes recrutées, des écarts au niveau des résultats signalés et la qualité inconnue des préparations utilisées. Les comparaisons manquaient d’un traitement contrôle actif. Les preuves disponibles suggèrent que le Cernilton est bien toléré et améliore modestement les symptômes urologiques globaux, notamment la nycturie. Des essais randomisés supplémentaires avec contrôle actif et placebo sont nécessaires pour évaluer l'efficacité clinique à long terme et l'innocuité du Cernilton.
- 11 May 2011
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2011 (5) , CD001042
Cernilton for benign prostatic hyperplasia
Authors have indicated they are not going to update this review. Cernilton dans l'hyperplasie prostatique bénigne Contexte L'hyperplasie prostatique bénigne (HPB), une hypertrophie non maligne de la prostate, peut provoquer des symptômes obstructifs et irritants des voies urinaires inférieures (SVUI). L'utilisation pharmacologique des plantes et des herbes (phytothérapie) pour le traitement des SVUI associés à une HPB est en constante progression. Le Cernilton, préparé à partir de pollen de fleur de seigle, Secale cereale, est l'un des nombreux agents phytothérapeutiques disponibles pour le traitement de l'HPB. Objectifs L'objectif de cette revue systématique est d'évaluer les effets du Cernilton sur les symptômes urinaires et les mesures de débit chez les hommes souffrant d'une hyperplasie prostatique bénigne (HPB). Stratégie de recherche documentaire Des essais ont été recherchés dans des bases de données générales et spécialisées informatisées (MEDLINE, EMBASE, Cochrane Library, Phytodok), en consultant les bibliographies et en contactant les fabricants et les chercheurs. Critères de sélection Les essais étaient éligibles à condition d'être : (1) des essais contrôlés randomisés ou des essais cliniques contrôlés comparant le Cernilton à un placebo ou à d'autres médicaments contre l'HPB chez les hommes souffrant d'HPB et (2) des résultats cliniques inclus comme des échelles de symptômes urologiques, des symptômes ou des mesures urodynamiques. Recueil et analyse des données Au moins deux évaluateurs indépendants ont extrait des informations concernant les patients, les interventions et les résultats à l'aide d'un formulaire standard. Le critère de jugement principal permettant de comparer les effets du Cernilton à ceux d'un placebo et de traitements standard contre l'HPB était une modification au niveau des échelles de symptômes urologiques. Les critères de jugement secondaires incluaient des modifications au niveau de la nycturie et des mesures urodynamiques (débit urinaire moyen et de pointe, volume résiduel, taille de la prostate). Le critère de jugement principal concernant les effets secondaires était le nombre d'hommes signalant des effets secondaires. Résultats principaux Des hommes, au nombre de 444, ont été recrutés dans deux essais contrôlés par placebo et deux essais comparatifs d'une durée variant de 12 à 24 semaines. Trois études utilisaient une méthode en double aveugle, bien que l'assignation secrète du traitement soit peu claire dans l'ensemble des études. Le Cernilton améliorait les « symptômes urinaires signalés » (pourcentage signalant des symptômes satisfaisants ou leur amélioration) par rapport à un placebo et au Tadenan. Le risque relatif (RR) pondéré d'une amélioration signalée était de 2,40 (IC à 95 % = 1,21 à 4,75) par rapport à un placebo et le RR pondéré était de 1,42 (IC à 95 % = 1,21 à 4,75) par rapport au Tadenan. Le Cernilton réduisait la nycturie par rapport à un placebo et au Paraprost. Comparé à un placebo, le RR pondéré était de 2,05 (IC à 95 % = 1,41 à 3,00) et comparée au Paraprost, la DMP était de - 0,40 fois par soir (IC à 95 % = - 0,73 à - 0,07). Le Cernilton n'était pas plus efficace qu'un placebo ou les agents de l'étude comparative à améliorer les taux de débit urinaire, le volume résiduel ou la taille de la prostate. Les événements indésirables étaient rares et légers. Le taux d'arrêts prématurés du Cernilton était de 4,8 % par rapport à 2,7 % pour le placebo et 5,2 % pour le Paraprost. Conclusions des auteurs Les essais concernant le Cernilton analysés étaient limités par une durée courte, un nombre limité de personnes recrutées, des écarts au niveau des résultats signalés et la qualité inconnue des préparations utilisées. Les comparaisons manquaient d’un traitement contrôle actif. Les preuves disponibles suggèrent que le Cernilton est bien toléré et améliore modestement les symptômes urologiques globaux, notamment la nycturie. Des essais randomisés supplémentaires avec contrôle actif et placebo sont nécessaires pour évaluer l'efficacité clinique à long terme et l'innocuité du Cernilton.
- Open Access
- 15 June 2010
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 152 (12) , 797-803
Systematic Review: Effective Management Strategies for Lactose Intolerance
Lactose intolerance resulting in gastrointestinal symptoms is a common health concern. Diagnosis and management of this condition remain unclear. To assess the maximum tolerable dose of lactose and interventions for reducing symptoms of lactose intolerance among persons with lactose intolerance and malabsorption. Multiple electronic databases, including MEDLINE and the Cochrane Library, for trials published in English from 1967 through November 2009. Randomized, controlled trials of individuals with lactose intolerance or malabsorption. Three investigators independently reviewed articles, extracted data, and assessed study quality. 36 unique randomized studies (26 on lactase- or lactose-hydrolyzed milk supplements, lactose-reduced milk, or tolerable doses of lactose; 7 on probiotics; 2 on incremental lactose administration for colonic adaptation; and 1 on another agent) met inclusion criteria. Moderate-quality evidence indicated that 12 to 15 g of lactose (approximately 1 cup of milk) is well tolerated by most adults. Evidence was insufficient that lactose-reduced solution or milk with a lactose content of 0 to 2 g, compared with greater than 12 g, is effective in reducing symptoms of lactose intolerance. Evidence for probiotics, colonic adaptation, and other agents was also insufficient. Most studies evaluated persons with lactose malabsorption rather than lactose intolerance. Variation in enrollment criteria, outcome reporting, and the composition and dosing of studied agents precluded pooling of results and limited interpretation. Most individuals with presumed lactose intolerance or malabsorption can tolerate 12 to 15 g of lactose. Additional studies are needed to determine the effectiveness of lactose intolerance treatment.
- 15 June 2010
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 152 (12) , 797-803
Open AccessSystematic Review: Effective Management Strategies for Lactose Intolerance
Lactose intolerance resulting in gastrointestinal symptoms is a common health concern. Diagnosis and management of this condition remain unclear. To assess the maximum tolerable dose of lactose and interventions for reducing symptoms of lactose intolerance among persons with lactose intolerance and malabsorption. Multiple electronic databases, including MEDLINE and the Cochrane Library, for trials published in English from 1967 through November 2009. Randomized, controlled trials of individuals with lactose intolerance or malabsorption. Three investigators independently reviewed articles, extracted data, and assessed study quality. 36 unique randomized studies (26 on lactase- or lactose-hydrolyzed milk supplements, lactose-reduced milk, or tolerable doses of lactose; 7 on probiotics; 2 on incremental lactose administration for colonic adaptation; and 1 on another agent) met inclusion criteria. Moderate-quality evidence indicated that 12 to 15 g of lactose (approximately 1 cup of milk) is well tolerated by most adults. Evidence was insufficient that lactose-reduced solution or milk with a lactose content of 0 to 2 g, compared with greater than 12 g, is effective in reducing symptoms of lactose intolerance. Evidence for probiotics, colonic adaptation, and other agents was also insufficient. Most studies evaluated persons with lactose malabsorption rather than lactose intolerance. Variation in enrollment criteria, outcome reporting, and the composition and dosing of studied agents precluded pooling of results and limited interpretation. Most individuals with presumed lactose intolerance or malabsorption can tolerate 12 to 15 g of lactose. Additional studies are needed to determine the effectiveness of lactose intolerance treatment.
- 7 October 2009
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 4,p. CD007360
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is a common condition in aging men causing lower urinary tract symptoms (LUTS). Treatment aims are to relieve symptoms and prevent disease progression. Of the different α‐1 adrenergic receptors (ARs) in the prostate, α‐1a receptors are known to be central to prostatic smooth‐muscle contraction. Recent studies have shown that patients with BPH may also have a predominance of α‐1d receptors. To evaluate the efficacy and adverse effects of naftopidil, a selective α‐1d oral alpha‐blocking agent for the treatment of LUTS associated with BPH. Systematic review of trials published January 1950 to January 2009. Sources included MEDLINE and bibliographies of retrieved articles and review articles. Eligible trials included: men diagnosed with symptomatic BPH; compared Naftopidil to placebo, control, or combination therapy; evaluated clinically relevant outcomes between randomized groups; had at least 4‐weeks follow up; and were published in English language. Participant demographics and comorbidities, enrollment criteria, outcomes, adverse events, numbers and reasons for dropouts were extracted onto standardized extraction forms by one reviewer. The mean change and per cent improvement from baseline in AUA (American Urological Association Symptom Score) and IPSS (International Prostate Symptom Score) scores and other efficacy outcomes for treatment and control groups were calculated. If feasible, the efficacy outcomes and adverse events data were pooled. Eight trials were eligible (N = 744 participants). All trials were conducted in Japan. Study duration ranged from 4 to 17 weeks. The mean age of participants was 68 years; pretreatment mean IPSS = 17.8 and mean peak urine flow (Qmax) = 9.5 mL/s (milliliters/second). No trials compared naftopidil to placebo. In 5 trials (N = 419), naftopidil in doses of 25 to 75 mg/d (milligrams/day) showed a mean IPSS improvement similar to low‐dose tamsulosin (0.2 mg/d) (8.4 versus 8.9 points). Compared to a phytotherapy preparation (eviprostat), naftopidil significantly improved total IPSS (‐5.9 versus 0.4; P < 0.0002). In one trial, the addition of anticholinergic drugs (oxybutynin or propiverine hydrochloride) to naftopidil did not offer any significant improvement for IPSS or Qmax in comparison to treatment with naftopidil alone. Although IPSS did not significantly differ between high‐ (75 mg/d) and low‐dose (25mg/d) naftopidil, high dose significantly improved Qmax compared to low dose (1.2 mL/s versus 0.2 mL/s). Adverse events reported were few, mild and similar to those seen with 0.2 mg/d tamsulosin. There are no data from placebo controlled trials regarding the efficacy of naftopidil in men with symptomatic BPH. Limited information suggests that treatment with naftopidil provides short‐term improvement in urinary symptom‐scale scores (total IPSS/AUA), QoL (quality of life) score, and urinary symptoms from baseline comparable to low‐dose tamsulosin. Adverse effects due to naftopidil were few and usually mild. Naftopidil用在治療良性前列腺肥大造成的下泌尿道症狀 良性前列腺肥大(BPH)常會造成老年男性的下泌尿道症狀(LUTS),治療目標是解除症狀並防止疾病惡化。在前列腺不同的α −1腎上腺激素性受體(ARs)中,α −1a受體被認為是主要控制前列腺的平滑肌收縮。最近的研究指出,患有良性前列腺肥大(BPH)的病人也同樣擁有大量的α −1d受體。 評估naftopidil的治療效益及副作用,naftopidil是一種α −1d選擇性的口服甲型阻斷劑,用來治療良性前列腺肥大(BPH)相關的下泌尿道症狀(LUTS)。 系統性的回顧發表自1950年1月至2009年1月的臨床試驗,資料來源包括MEDLINE及用以回顧的原創文章及回顧性文章的參考書目。 納入回顧的試驗必須要是有診斷為有症狀的良性前列腺肥大(BPH)男性;比較Naftopidil及安慰劑對照的臨床試驗或併用療法;在隨機的組別間評估臨床相關的結果;至少追蹤四周;用英文發表之試驗。 由單一專家來統計受試者的人口統計學資料、合併的併發症、納入的條件、結果、副作用、退出試驗的人數及原因。對於AUA評分(美國泌尿科協會症狀評分表) and IPSS評分(國際前列腺症狀評分表),其他藥物的治療效果,及對照組的平均變化及改善的百分比,也會統計計算。若可以的話,對於治療效果及副作用資料也會ㄧ併納入統計。 共有8個符合條件的臨床試驗(N = 744),所有臨床試驗皆由日本主導完成,試驗研究時間從4周到17周,平均受試者年齡為68歲,治療前的平均IPSS為17.8分,平均最大尿流速(Qmax)為9.5毫升/秒(mL/s),沒有臨床比較naftopidil及安慰劑。在五個臨床試驗中,在每天使用naftopidil劑量為25到75毫克的病患,與每天使用低劑量tamsulosin (0.2 mg/d)的病患比較,平均IPSS的進步是差不多的(8.4 分比8.9 分) 。與草本藥物治療比較(eviprostat),在IPSS總分上,naftopidil有明顯的進步(−5.9分比上0.4; P < 0.0002). naftopidil加上抗膽鹼激素藥物(oxybutynin或propiverine hydrochloride)的臨床試驗顯示,額外加上的藥物無法在IPSS或 Qmax上得到明顯的改善。雖然高劑量(75 mg/d)及低劑量(25 mg/d)naftopidil在IPSS上的改善沒有明顯差異,但在Qmax上高劑量(75 mg/d)比起低劑量(25 mg/d)naftopidil有顯著地改善。目前所知的藥物副作用則非常少,輕微的副作用,或是跟0.2 mg/d tamsulosin一樣的副作用。 naftopidil在有症狀的前列腺肥大男性的治療,目前仍沒有安慰劑控制的臨床試驗顯示效益。對於naftopidil的治療有限的資料顯示,在泌尿道症狀評分 (IPSS/AUA總分) 上、QoL...
- 7 October 2009
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 4,p. CD007360
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is a common condition in aging men causing lower urinary tract symptoms (LUTS). Treatment aims are to relieve symptoms and prevent disease progression. Of the different α‐1 adrenergic receptors (ARs) in the prostate, α‐1a receptors are known to be central to prostatic smooth‐muscle contraction. Recent studies have shown that patients with BPH may also have a predominance of α‐1d receptors. To evaluate the efficacy and adverse effects of naftopidil, a selective α‐1d oral alpha‐blocking agent for the treatment of LUTS associated with BPH. Systematic review of trials published January 1950 to January 2009. Sources included MEDLINE and bibliographies of retrieved articles and review articles. Eligible trials included: men diagnosed with symptomatic BPH; compared Naftopidil to placebo, control, or combination therapy; evaluated clinically relevant outcomes between randomized groups; had at least 4‐weeks follow up; and were published in English language. Participant demographics and comorbidities, enrollment criteria, outcomes, adverse events, numbers and reasons for dropouts were extracted onto standardized extraction forms by one reviewer. The mean change and per cent improvement from baseline in AUA (American Urological Association Symptom Score) and IPSS (International Prostate Symptom Score) scores and other efficacy outcomes for treatment and control groups were calculated. If feasible, the efficacy outcomes and adverse events data were pooled. Eight trials were eligible (N = 744 participants). All trials were conducted in Japan. Study duration ranged from 4 to 17 weeks. The mean age of participants was 68 years; pretreatment mean IPSS = 17.8 and mean peak urine flow (Qmax) = 9.5 mL/s (milliliters/second). No trials compared naftopidil to placebo. In 5 trials (N = 419), naftopidil in doses of 25 to 75 mg/d (milligrams/day) showed a mean IPSS improvement similar to low‐dose tamsulosin (0.2 mg/d) (8.4 versus 8.9 points). Compared to a phytotherapy preparation (eviprostat), naftopidil significantly improved total IPSS (‐5.9 versus 0.4; P < 0.0002). In one trial, the addition of anticholinergic drugs (oxybutynin or propiverine hydrochloride) to naftopidil did not offer any significant improvement for IPSS or Qmax in comparison to treatment with naftopidil alone. Although IPSS did not significantly differ between high‐ (75 mg/d) and low‐dose (25mg/d) naftopidil, high dose significantly improved Qmax compared to low dose (1.2 mL/s versus 0.2 mL/s). Adverse events reported were few, mild and similar to those seen with 0.2 mg/d tamsulosin. There are no data from placebo controlled trials regarding the efficacy of naftopidil in men with symptomatic BPH. Limited information suggests that treatment with naftopidil provides short‐term improvement in urinary symptom‐scale scores (total IPSS/AUA), QoL (quality of life) score, and urinary symptoms from baseline comparable to low‐dose tamsulosin. Adverse effects due to naftopidil were few and usually mild. Naftopidil用在治療良性前列腺肥大造成的下泌尿道症狀 良性前列腺肥大(BPH)常會造成老年男性的下泌尿道症狀(LUTS),治療目標是解除症狀並防止疾病惡化。在前列腺不同的α −1腎上腺激素性受體(ARs)中,α −1a受體被認為是主要控制前列腺的平滑肌收縮。最近的研究指出,患有良性前列腺肥大(BPH)的病人也同樣擁有大量的α −1d受體。 評估naftopidil的治療效益及副作用,naftopidil是一種α −1d選擇性的口服甲型阻斷劑,用來治療良性前列腺肥大(BPH)相關的下泌尿道症狀(LUTS)。 系統性的回顧發表自1950年1月至2009年1月的臨床試驗,資料來源包括MEDLINE及用以回顧的原創文章及回顧性文章的參考書目。 納入回顧的試驗必須要是有診斷為有症狀的良性前列腺肥大(BPH)男性;比較Naftopidil及安慰劑對照的臨床試驗或併用療法;在隨機的組別間評估臨床相關的結果;至少追蹤四周;用英文發表之試驗。 由單一專家來統計受試者的人口統計學資料、合併的併發症、納入的條件、結果、副作用、退出試驗的人數及原因。對於AUA評分(美國泌尿科協會症狀評分表) and IPSS評分(國際前列腺症狀評分表),其他藥物的治療效果,及對照組的平均變化及改善的百分比,也會統計計算。若可以的話,對於治療效果及副作用資料也會ㄧ併納入統計。 共有8個符合條件的臨床試驗(N = 744),所有臨床試驗皆由日本主導完成,試驗研究時間從4周到17周,平均受試者年齡為68歲,治療前的平均IPSS為17.8分,平均最大尿流速(Qmax)為9.5毫升/秒(mL/s),沒有臨床比較naftopidil及安慰劑。在五個臨床試驗中,在每天使用naftopidil劑量為25到75毫克的病患,與每天使用低劑量tamsulosin (0.2 mg/d)的病患比較,平均IPSS的進步是差不多的(8.4 分比8.9 分) 。與草本藥物治療比較(eviprostat),在IPSS總分上,naftopidil有明顯的進步(−5.9分比上0.4; P < 0.0002). naftopidil加上抗膽鹼激素藥物(oxybutynin或propiverine hydrochloride)的臨床試驗顯示,額外加上的藥物無法在IPSS或 Qmax上得到明顯的改善。雖然高劑量(75 mg/d)及低劑量(25 mg/d)naftopidil在IPSS上的改善沒有明顯差異,但在Qmax上高劑量(75 mg/d)比起低劑量(25 mg/d)naftopidil有顯著地改善。目前所知的藥物副作用則非常少,輕微的副作用,或是跟0.2 mg/d tamsulosin一樣的副作用。 naftopidil在有症狀的前列腺肥大男性的治療,目前仍沒有安慰劑控制的臨床試驗顯示效益。對於naftopidil的治療有限的資料顯示,在泌尿道症狀評分 (IPSS/AUA總分) 上、QoL...
- 1 January 2009
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 30 (1) , 81-87
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer
- 1 January 2009
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 30 (1) , 81-87
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer
- 8 October 2008
- Published by Wiley
- No. 4
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
- 8 October 2008
- Published by Wiley
- No. 4
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
- 1 September 2008
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 180 (3) , 820-829
Association Between Hospital and Surgeon Radical Prostatectomy Volume and Patient Outcomes: A Systematic Review
We examined the association between hospital and surgeon volume, and patient outcomes after radical prostatectomy. Databases were searched from 1980 to November 2007 to identify controlled studies published in English. Information on study design, hospital and surgeon annual radical prostatectomy volume, hospital status and patient outcome rates were abstracted using a standardized protocol. Data were pooled with random effects models. A total of 17 original investigations reported patient outcomes in categories of hospital and/or surgeon annual number of radical prostatectomies, and met inclusion criteria. Hospitals with volumes above the mean (43 radical prostatectomies per year) had lower surgery related mortality (rate of difference 0.62, 95% CI 0.47-0.81) and morbidity (rate difference -9.7%, 95% CI -15.8, -3.6). Teaching hospitals had an 18% (95% CI -26, -9) lower rate of surgery related complications. Surgeon volume was not significantly associated with surgery related mortality or positive surgical margins. However, the rate of late urinary complications was 2.4% lower (95% CI -5, -0.1) and the rate of long-term incontinence was 1.2% lower (95% CI -2.5, -0.1) for each 10 additional radical prostatectomies performed by the surgeon annually. Length of stay was lower, corresponding to surgeon volume. Higher provider volumes are associated with better outcomes after radical prostatectomy. Greater understanding of factors leading to this volume-outcome relationship, and the potential benefits and harms of increased regionalization is needed.
- 1 September 2008
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 180 (3) , 820-829
Association Between Hospital and Surgeon Radical Prostatectomy Volume and Patient Outcomes: A Systematic Review
We examined the association between hospital and surgeon volume, and patient outcomes after radical prostatectomy. Databases were searched from 1980 to November 2007 to identify controlled studies published in English. Information on study design, hospital and surgeon annual radical prostatectomy volume, hospital status and patient outcome rates were abstracted using a standardized protocol. Data were pooled with random effects models. A total of 17 original investigations reported patient outcomes in categories of hospital and/or surgeon annual number of radical prostatectomies, and met inclusion criteria. Hospitals with volumes above the mean (43 radical prostatectomies per year) had lower surgery related mortality (rate of difference 0.62, 95% CI 0.47-0.81) and morbidity (rate difference -9.7%, 95% CI -15.8, -3.6). Teaching hospitals had an 18% (95% CI -26, -9) lower rate of surgery related complications. Surgeon volume was not significantly associated with surgery related mortality or positive surgical margins. However, the rate of late urinary complications was 2.4% lower (95% CI -5, -0.1) and the rate of long-term incontinence was 1.2% lower (95% CI -2.5, -0.1) for each 10 additional radical prostatectomies performed by the surgeon annually. Length of stay was lower, corresponding to surgeon volume. Higher provider volumes are associated with better outcomes after radical prostatectomy. Greater understanding of factors leading to this volume-outcome relationship, and the potential benefits and harms of increased regionalization is needed.